Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis.

Adv Ther · 2026 · PMC13065559 · PMID 41706313

Europe PMC DOI

hedged sentences

0.2100

closest p · 4.2× alpha

0.2100

boldest claim

The sentences

did not reach statistical significancep = 0.210not close (p > 0.1)

Patients aged ≥ 45 years on DRF had a numerically lower annualized rate of SIs compared with patients on anti-CD20s [RR: 0.77 (95% CI 0.52–1.15)] but this did not reach statistical significance ( p = 0.210).

also in 61,332 other papers

a numerical trendno p-value reported

This reduces statistical power despite a numerical trend toward higher SI rates with anti-CD20 therapy.

also in 708 other papers

did not achieve significanceno p-value reported

This explains why non-COVID comparisons, particularly for severe infections in older patients, did not achieve significance despite numerical differences.

also in 541 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.